Eli Lilly and Company $LLY Shares Sold by Sivik Global Healthcare LLC

Sivik Global Healthcare LLC reduced its holdings in Eli Lilly and Company (NYSE:LLY) by 15.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,230 shares of the company’s stock after selling 770 shares during the period. Eli Lilly and Company comprises 3.0% of Sivik Global Healthcare LLC’s holdings, making the stock its 15th biggest position. Sivik Global Healthcare LLC’s holdings in Eli Lilly and Company were worth $4,894,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of LLY. BlackRock Inc. grew its stake in shares of Eli Lilly and Company by 1.6% during the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock worth $81,009,981,000 after purchasing an additional 1,046,558 shares during the period. State Street Corp increased its holdings in Eli Lilly and Company by 1.7% in the second quarter. State Street Corp now owns 36,215,754 shares of the company’s stock valued at $43,438,262,000 after buying an additional 605,752 shares in the last quarter. Bank of America Corp DE acquired a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at about $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Eli Lilly and Company by 1.9% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company’s stock valued at $8,647,153,000 after purchasing an additional 137,364 shares in the last quarter. Finally, Jennison Associates LLC increased its stake in shares of Eli Lilly and Company by 7.9% in the 2nd quarter. Jennison Associates LLC now owns 5,461,416 shares of the company’s stock valued at $6,550,587,000 after purchasing an additional 400,538 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of NYSE LLY traded down $13.92 during midday trading on Tuesday, hitting $1,168.70. The stock had a trading volume of 658,782 shares, compared to its average volume of 2,945,984. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The stock has a 50 day simple moving average of $1,175.57 and a 200-day simple moving average of $1,100.31. The company has a market capitalization of $1.10 trillion, a PE ratio of 39.25, a P/E/G ratio of 1.47 and a beta of 0.46. Eli Lilly and Company has a 1 year low of $783.85 and a 1 year high of $1,292.65.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The firm had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. During the same period in the previous year, the business posted $6.31 earnings per share. Eli Lilly and Company’s quarterly revenue was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, sell-side analysts expect that Eli Lilly and Company will post 36.19 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on LLY shares. Morgan Stanley upped their price target on Eli Lilly and Company from $1,419.00 to $1,430.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. TD Cowen reissued a “buy” rating and issued a $1,250.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, September 22nd. UBS Group set a $1,376.00 price objective on Eli Lilly and Company in a research report on Friday, August 7th. Bank of America upped their target price on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a research note on Friday, July 10th. Finally, Truist Financial boosted their price target on shares of Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the stock a “buy” rating in a report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $1,313.43.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analysts remain optimistic about Lilly’s earnings and growth prospects. Erste Group raised its FY2026 EPS estimate to $36.55 from $36.45 and its FY2027 forecast to $47.30, while RBC reiterated an “outperform” rating with a $1,500 price target. RBC reiterates outperform rating
• Positive Sentiment: Strong demand for Zepbound and other cardiometabolic medicines is supporting expectations that Lilly could raise its full-year revenue outlook. Analysts and investors also see substantial long-term potential in retatrutide, which could become a larger growth driver than Zepbound if clinical results and commercialization proceed successfully. Lilly revenue outlook
• Positive Sentiment: Phase 3b data for a Taltz-Zepbound combination showed improved skin clearance and weight loss in patients with plaque psoriasis and obesity, potentially expanding Lilly’s ability to target overlapping inflammatory and metabolic conditions. Taltz and Zepbound Phase 3b data
• Positive Sentiment: Lilly is collaborating with Prelude Therapeutics to evaluate a cancer drug combination involving PRT13722, Verzenio and Inluriyo, adding another potential pipeline opportunity. Prelude collaboration with Lilly
• Neutral Sentiment: Lilly’s revenue growth substantially exceeds that of major pharmaceutical peers, but its premium earnings multiple leaves less room for execution mistakes. Investor confidence therefore depends heavily on the company’s pipeline and future obesity-drug launches. Lilly valuation and growth outlook
• Negative Sentiment: A combination treatment produced more weight loss than Zepbound alone but also had materially higher discontinuation rates, raising questions about tolerability, adherence and the commercial potential of future obesity therapies. Lilly weight-loss combination study
• Negative Sentiment: Retatrutide is already facing illicit online sales before approval, highlighting potential regulatory, safety and brand risks for Lilly’s highly anticipated obesity pipeline. Retatrutide black-market sales

Insider Activity

In related news, CAO Donald Zakrowski sold 2,000 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the sale, the chief accounting officer owned 1,526 shares of the company’s stock, valued at approximately $1,808,325.26. This trade represents a 56.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the transaction, the executive vice president owned 11,875 shares in the company, valued at approximately $14,131,250. The trade was a 29.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,500 shares of company stock worth $15,958,170 over the last ninety days. Corporate insiders own 0.14% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.